Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23525967 | 1.00 | SOS1 (0.32) | SOS1HTT | |
| SCHEMBL29945711 | 1.00 | SOS1 (0.32) | SOS1HTT | |
| SCHEMBL30454856 | 1.00 | SOS1 (0.32) | SOS1HTT | |
| SCHEMBL23525970 | 1.00 | SOS1 (0.32) | SOS1HTT | |
| SCHEMBL23526053 | 1.00 | SOS1 (0.32) | SOS1HTT | |
| SCHEMBL23526055 | 1.00 | SOS1 (0.32) | SOS1HTT | |
| SCHEMBL23525971 | 1.00 | SOS1 (0.32) | SOS1HTT | |
| SCHEMBL14977275 | 0.86 | HTT (0.42) | HTT | |
| SCHEMBL25472038 | 0.86 | HTT (0.42) | HTT | |
| SCHEMBL28934653 | 0.86 | HTT (0.42) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543450-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119546304-A | Salts of SOS1 inhibitors | 米拉蒂治疗公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119462626-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-115135315-B | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| WO-2023250165-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-4076418-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115135315-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2022-09-30 | — | — | CN | disclosed |